Last reviewed · How we verify
Camrelizumab combined TPC chemotherapy
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, combined with traditional chemotherapy (TPC) to enhance therapeutic effect.
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, combined with traditional chemotherapy (TPC) to enhance therapeutic effect. Used for Advanced or metastatic non-small cell lung cancer (NSCLC), Hepatocellular carcinoma, Esophageal squamous cell carcinoma.
At a glance
| Generic name | Camrelizumab combined TPC chemotherapy |
|---|---|
| Also known as | camrelizumab plus nab-TPC chemotherapy, nab-paclitaxel, cisplatin and capecitabine |
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and reversing immune exhaustion. This combination approach pairs checkpoint inhibition with conventional chemotherapy agents to achieve synergistic anti-tumor immunity and direct cytotoxic effects.
Approved indications
- Advanced or metastatic non-small cell lung cancer (NSCLC)
- Hepatocellular carcinoma
- Esophageal squamous cell carcinoma
Common side effects
- Fatigue
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Decreased appetite
- Anemia
Key clinical trials
- Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma (PHASE3)
- Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial (PHASE3)
- A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camrelizumab combined TPC chemotherapy CI brief — competitive landscape report
- Camrelizumab combined TPC chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI